Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites
Phase of Trial: Phase I
Latest Information Update: 07 Oct 2015
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV-1 infections; Rheumatoid arthritis
- Focus Pharmacokinetics
- 05 Apr 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record as reported by ClinicalTrials.gov record.
- 14 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
- 25 Nov 2013 New trial record